Transformation in healthcare is ongoing and purpose-driven. It’s not a fleeting trend but a continuous process rooted in ...

Recently, Vermont senator Bernie Sanders and Maine senator Angus King introduced a bill to ban prescription drug advertising ...

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Viseven announced a new AI agent for its content creation platform eWizard. The new agent, called eVa, is able to communicate ...

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...